gene in people relapsing just after treatment Using the BCL2 antagonist venetoclax. 66 Resistance to those brokers has long been affiliated with these mutations in around 70% of conditions, Whilst they tend to be subclonal as well as their unique job producing resistance needs to be confirmed. ??